SYNLOGIC, INC.
Close on Oct 19, 2026
- Market cap
- $13.29M
- P/E (TTM)
- –
- Dividend yield
- –
About Synlogic
Pharmaceutical Preparations, SIC 2834
Synlogic, Inc. is a biopharmaceutical company that formerly developed novel therapeutics using synthetic biology to treat serious illnesses, specifically rare metabolic diseases. The company’s pipeline centered on genetically engineered bacterial therapeutics, known as Synthetic Biotics, designed to target conditions such as phenylketonuria, homocystinuria, hyperoxaluria, hyperuricemia, and hyperammonemia, along with inflammatory and autoimmune disorders. Following the discontinuation of its lead clinical study, Synlogic operates as a public shell company whose primary activities involve reviewing strategic alternatives, which include potential mergers or an outright sale of the business.
The company operates with a single full-time employee and maintains no ongoing clinical trials or active research and development programs. Its intellectual property portfolio includes over 114 company-owned patents and patent applications across the United States and international jurisdictions, covering bacterial chassis, genetic circuitry, and specialized manufacturing processes. Synlogic maintains its principal executive offices in Winchester, Massachusetts.
Summary of the business section of Synlogic's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SYNLOGIC, INC.
- Founded
- 2007
- Headquarters
- Winchester, MA
- Address
- Po Box 30 01890
- Phone
- (617) 659-2802
- Website
- synlogictx.com
- Employees
- 1, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, MA
Stock & identifiers
- Ticker
- SYBX
- Exchange
- OTC
- IPO date
- Oct 1, 2015
- Shares outstanding
- 12M, Aug 4, 2026
- Public float
- $4.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Nov 9, 2023; 1-for-7 reverse, Aug 28, 2017; 1-for-7.25 reverse, Aug 25, 2017
- SEC CIK
- 1527599
- CUSIP
- 87166L209
- ISIN
- US87166L2097
- LEI
- 5493007C6UCNXL4HOI66
- EIN
- 26-1824804
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mary Beth Dooley | See Remarks below | 12,744 |
| Mohamad Makhzoumi | Director | – |
| Scott D. Sandell | Director | 7,151,713 |
| Anthony A. Florence Jr. | Director | 4,228,940 |
| New Enterprise Associates 14, L.P. | Director | 2,114,375 |
| NEA Partners 14, L.P. | Director | – |
| Nea 14 Gp, Ltd | Director | 4,228,940 |
| James P. Flynn | Director | 15,000 |
| Richard P. Shea | Director | 15,506 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Dr Aoife Brennan | $1.12M | $807.47K | $486.49K | $4 | – |
| FY2024 Mr Antoine Awad | $1.26M | $1.13M | $486.49K | $4 | – |
| FY2023 Dr Aoife Brennan | $1.22M | $808.64K | $666.60K | $11 | – |
| FY2022 Dr Aoife Brennan | $1.68M | $659.01K | $876.85K | $31 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 5, 2026, we had one full-time employee, primarily engaged in the assessment of strategic transactions, as directed by the Company's board of directors.”
Corporate history
Events identified from SEC filings